(3R,4R,5R)-3-FLUORO-4-HYDROXY-5-(HYDROXYMETHYL)-3-METHYLDIHYDROFURAN-2(3H)-ONE, 95.0%, 5g

Ethyl 4-(methylamino)-2-(methylsulfanyl)-5-pyrimidinecarboxylate, 95.0%, 10g

5,6,7,8-Tetrahydro-1,7-naphthyridine dihydrochloride, 95.0%, 100mg

3,3-DIMETHYLPYRROLIDINE-2,5-DIONE, 95.0%, 5g

3-(BOC-AMINO)-BICYCLO[1.1.1]PENTANE-1-CARBALDEHYDE, 95.0%, 250mg

tert-Butyl 3,3-difluorooctahydro-5H-pyrrolo[3,2-c]pyridine-5-carboxylate, 97%, 250mg

E-Plan-Phase EPLPHi 20x/0,40 unendlich korrigiertes IOS-Objektiv. Arbeitsabstand 2,61 mm

2-((6-Chloro-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl)benzonitrile, 95.0%, 1g

(R,R)-1,1'-Bis(a-hydroxyphenylmethyl)ferrocene, 98%, 1g

5,5'-Bis(diphenylphosphino)-2,2,2',2'-tetrafluoro-4,4'-bi-1,3-benzodioxole, 98%, 100mg

5-Hydroxy isatoic anhydride, 95.0%, 5g

3-(6-Chloro-1H-benzoimidazol-2-yl)-propionic acid, 95.0%, 1g

3,5-Difluoronitrobenzene, 99.0%, 1g